|
DE19827457C1
(de)
*
|
1998-06-19 |
2000-03-02 |
Medigene Ag |
Strukturprotein von AAV, seine Herstellung und Verwendung
|
|
US6759237B1
(en)
|
1998-11-05 |
2004-07-06 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
|
|
AU780231B2
(en)
*
|
1998-11-10 |
2005-03-10 |
University Of North Carolina At Chapel Hill, The |
Virus vectors and methods of making and administering the same
|
|
US7314912B1
(en)
|
1999-06-21 |
2008-01-01 |
Medigene Aktiengesellschaft |
AAv scleroprotein, production and use thereof
|
|
DE19933288A1
(de)
|
1999-07-15 |
2001-01-18 |
Medigene Ag |
Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
|
|
DE19933719A1
(de)
*
|
1999-07-19 |
2001-01-25 |
Medigene Ag |
Strukturprotein in Adeno-assoziiertem Virus mit veränderten chromatographischen Eigenschaften, seine Herstellung und Verwendung
|
|
US7115391B1
(en)
*
|
1999-10-01 |
2006-10-03 |
Genovo, Inc. |
Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
|
|
CA2373110A1
(en)
*
|
2000-03-14 |
2001-09-20 |
Neurologix, Inc. |
Production of chimeric capsid vectors
|
|
US7638120B2
(en)
*
|
2000-03-14 |
2009-12-29 |
Thomas Jefferson University |
High transgene expression of a pseudotyped adeno-associated virus type
|
|
US7056502B2
(en)
*
|
2000-04-28 |
2006-06-06 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids
|
|
US7201898B2
(en)
*
|
2000-06-01 |
2007-04-10 |
The University Of North Carolina At Chapel Hill |
Methods and compounds for controlled release of recombinant parvovirus vectors
|
|
WO2002000924A2
(en)
*
|
2000-06-28 |
2002-01-03 |
Institut National De La Recherche Scientifique |
Viral phospholipase a2 enzymes, anti-viral agents and methods of use
|
|
US7749492B2
(en)
*
|
2001-01-05 |
2010-07-06 |
Nationwide Children's Hospital, Inc. |
AAV vectors and methods
|
|
WO2002053703A2
(en)
*
|
2001-01-05 |
2002-07-11 |
Children's Hospital, Inc. |
Aav2 vectors and methods
|
|
DE10120265A1
(de)
*
|
2001-04-25 |
2002-11-14 |
Deutsches Krebsforsch |
AAV-Helferplasmide zur Helfervirus-freien Verpackung und Pseudotypisierung von AAV-Vektoren
|
|
US8067156B2
(en)
*
|
2001-05-31 |
2011-11-29 |
The Rockefeller University |
Method for generating replication defective viral vectors that are helper free
|
|
US6859916B1
(en)
|
2001-06-03 |
2005-02-22 |
Cadence Design Systems, Inc. |
Polygonal vias
|
|
US6905678B2
(en)
*
|
2001-07-07 |
2005-06-14 |
Crucell Holland B.V. |
Gene delivery vectors with cell type specificity for mesenchymal stem cells
|
|
US8241622B2
(en)
*
|
2001-07-13 |
2012-08-14 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
|
|
JP2005503418A
(ja)
*
|
2001-09-14 |
2005-02-03 |
ユニベルシテ ピエール エ マリー キュリー（パリ シズエム） |
治療的ワクチン接種法、ｈｉｖ逆転写酵素の突然変異ペプチドならびにワクチン接種及び診断目的のためのそれらの使用
|
|
DE10210139A1
(de)
*
|
2002-03-07 |
2003-10-23 |
Medigene Ag |
Helferkonstrukte für die Herstellung hybrider rAAV-Partikel unterschiedlicher AAV-Serotypen
|
|
AU2003223497A1
(en)
*
|
2002-04-05 |
2003-10-27 |
Centocor, Inc. |
Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
|
|
WO2003093440A2
(en)
*
|
2002-04-30 |
2003-11-13 |
University Of Florida |
Methods and compositions for expressing a nucleic acid in a dendritic cell
|
|
AU2003274397A1
(en)
*
|
2002-06-05 |
2003-12-22 |
University Of Florida |
Production of pseudotyped recombinant aav virions
|
|
KR100535325B1
(ko)
*
|
2002-09-24 |
2005-12-09 |
한국생명공학연구원 |
Ａａｖ 유전자 전달체 제조용 헬퍼 플라스미드
|
|
US20040208847A1
(en)
*
|
2003-03-28 |
2004-10-21 |
Fabienne Rolling |
Method and vectors for selectively transducing retinal pigment epithelium cells
|
|
SI1633772T1
(sl)
*
|
2003-06-19 |
2016-06-30 |
Genzyme Corporation |
AAV virioni z zmanjšano imunoreaktivnostjo in uporaba za ta namen
|
|
US9441244B2
(en)
*
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
US9233131B2
(en)
|
2003-06-30 |
2016-01-12 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
US7972593B2
(en)
*
|
2004-06-10 |
2011-07-05 |
Saint Louis University |
Delivery of therapeutic agents to the bone
|
|
US20100132058A1
(en)
|
2004-07-23 |
2010-05-27 |
Diatchenko Luda B |
Methods and materials for determining pain sensitivity and predicting and treating related disorders
|
|
JP5136766B2
(ja)
*
|
2004-12-15 |
2013-02-06 |
ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
キメラベクター
|
|
ES2525067T3
(es)
|
2005-04-07 |
2014-12-17 |
The Trustees Of The University Of Pennsylvania |
Método de incremento de la función de un vector de AAV
|
|
WO2007084773A2
(en)
*
|
2006-01-20 |
2007-07-26 |
University Of North Carolina At Chapel Hill |
Enhanced production of infectious parvovirus vectors in insect cells
|
|
US7867484B2
(en)
|
2006-01-27 |
2011-01-11 |
University Of North Carolina At Chapel Hill |
Heparin and heparan sulfate binding chimeric vectors
|
|
CA2638913A1
(en)
|
2006-02-10 |
2007-09-07 |
The University Of Cincinnati |
Phosphatase inhibitor protein-1 as a regulator of cardiac function
|
|
US7588772B2
(en)
|
2006-03-30 |
2009-09-15 |
Board Of Trustees Of The Leland Stamford Junior University |
AAV capsid library and AAV capsid proteins
|
|
ES2535877T3
(es)
|
2006-06-19 |
2015-05-18 |
Asklepios Biopharmaceutical, Inc. |
Genes de Factor VIII y Factor IX modificados y vectores para la terapia génica
|
|
WO2008054713A2
(en)
*
|
2006-10-30 |
2008-05-08 |
Thomas Jefferson University |
Tissue specific gene therapy treatment
|
|
ES2714007T3
(es)
|
2007-04-09 |
2019-05-24 |
Univ Florida |
Composiciones de vectores rAAV que tienen proteínas de la cápside modificadas en tirosina y métodos para su uso
|
|
EP2012122A1
(en)
*
|
2007-07-06 |
2009-01-07 |
Medigene AG |
Mutated parvovirus structural proteins as vaccines
|
|
EP2019143A1
(en)
|
2007-07-23 |
2009-01-28 |
Genethon |
CNS gene delivery using peripheral administration of AAV vectors
|
|
EP2058401A1
(en)
|
2007-10-05 |
2009-05-13 |
Genethon |
Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
|
|
WO2009105135A1
(en)
|
2008-02-19 |
2009-08-27 |
Celladon Corporation |
Compositions for enhanced uptake of viral vectors in the myocardium
|
|
WO2009108274A2
(en)
*
|
2008-02-26 |
2009-09-03 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for adeno-associated virus (aav) with hi loop mutations
|
|
AU2009332883B2
(en)
*
|
2008-12-22 |
2015-05-21 |
Oncos Therapeutics Oy |
Oncolytic adenoviral vectors and methods and uses related thereto
|
|
WO2010093784A2
(en)
|
2009-02-11 |
2010-08-19 |
The University Of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
|
US20120093775A1
(en)
|
2009-03-27 |
2012-04-19 |
Proyecto De Biomedicina Cima, S.L. |
Methods and compositions for the treatment of cirrhosis and liver fibrosis
|
|
EP2425000B1
(en)
*
|
2009-04-30 |
2019-02-20 |
The Trustees Of The University Of Pennsylvania |
Compositions for targeting conducting airway cells comprising adeno-associated virus constructs
|
|
WO2011032100A1
(en)
|
2009-09-11 |
2011-03-17 |
Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Inhibitors of kshv vil6 and human il6
|
|
BR112012010755A2
(pt)
|
2009-11-05 |
2015-09-22 |
Proyecto Biomedicina Cima Sl |
constructo de gene que permite a expressão hepato-específica induzível de um polinucleotídeo de interesse em resposta a um agente indutor, vetor, genoma viral recombinante, vírion, método in vitro para a expressão de um polinucleotídeo de interesse em uma célula de origem hepática, composição farmacêutica e operador-promotor bi-direcional induzível adequado para a expressão hepato-específica induzível de dois polinucleotídeos de interesse por um agente indutor
|
|
EP2524037B1
(en)
|
2010-01-12 |
2018-05-16 |
The University Of North Carolina At Chapel Hill |
Restrictive inverted terminal repeats for viral vectors
|
|
WO2011094198A1
(en)
|
2010-01-28 |
2011-08-04 |
The Children's Hospital Of Philadelphia Research Institute, Abramson Research Center |
A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
|
|
EP2534172A2
(en)
*
|
2010-02-12 |
2012-12-19 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Compositions and methods for preventing or treating a human parvovirus infection
|
|
DK2542260T3
(en)
*
|
2010-03-05 |
2016-06-06 |
Intervet Int Bv |
Recombinantly weakening parvovirus
|
|
WO2011126808A2
(en)
|
2010-03-29 |
2011-10-13 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
BR112012026095A2
(pt)
|
2010-04-14 |
2015-09-15 |
Emd Millipore Corp |
métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
|
|
EP2397542A1
(en)
*
|
2010-06-17 |
2011-12-21 |
Deutsches Krebsforschungszentrum |
Modified parvovirus having enhanced anti-tumour efficacy
|
|
AU2011276328C1
(en)
|
2010-07-06 |
2016-01-21 |
Novartis Ag |
Norovirus derived immunogenic compositions and methods
|
|
EP2605798A1
(en)
|
2010-07-12 |
2013-06-26 |
Universidad Autònoma de Barcelona |
Gene therapy composition for use in diabetes treatment
|
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
WO2012109570A1
(en)
|
2011-02-10 |
2012-08-16 |
The University Of North Carolina At Chapel Hill |
Viral vectors with modified transduction profiles and methods of making and using the same
|
|
EP2675484B1
(en)
|
2011-02-14 |
2018-05-30 |
The Children's Hospital of Philadelphia |
Improved aav8 vector with enhanced functional activity and methods of use thereof
|
|
CN105755044A
(zh)
|
2011-04-22 |
2016-07-13 |
加利福尼亚大学董事会 |
具有变异衣壳的腺相关病毒病毒体及其使用方法
|
|
JP6198278B2
(ja)
|
2011-09-08 |
2017-09-20 |
ユニキュアー アイピー ビー．ブイ． |
Ａａｖ調製物からの混入ウイルスの除去
|
|
WO2013052915A2
(en)
|
2011-10-05 |
2013-04-11 |
Genelux Corporation |
Method for detecting replication or colonization of a biological therapeutic
|
|
US20140087362A1
(en)
|
2012-03-16 |
2014-03-27 |
Aladar A. Szalay |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
|
WO2013158265A1
(en)
|
2012-04-20 |
2013-10-24 |
Genelux Corporation |
Imaging methods for oncolytic virus therapy
|
|
WO2013170078A1
(en)
|
2012-05-09 |
2013-11-14 |
Oregon Health & Science University |
Adeno associated virus plasmids and vectors
|
|
US10294281B2
(en)
|
2012-05-15 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
High-transduction-efficiency rAAV vectors, compositions, and methods of use
|
|
US12358954B2
(en)
|
2012-05-15 |
2025-07-15 |
University Of Florida Research Foundation, Incorporated |
Capsid-modified rAAV vector compositions and methods therefor
|
|
US20150182637A1
(en)
|
2012-06-21 |
2015-07-02 |
Association Institut De Myologie |
Widespread gene delivery of gene therapy vectors
|
|
EP2692868A1
(en)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
|
|
EP2900686B1
(en)
|
2012-09-28 |
2020-06-10 |
The University of North Carolina At Chapel Hill |
Aav vectors targeted to oligodendrocytes
|
|
US20140140959A1
(en)
|
2012-10-05 |
2014-05-22 |
Aladar A. Szalay |
Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
|
|
ES2667209T3
(es)
|
2013-03-14 |
2018-05-10 |
Asklepios Biopharmaceutical, Inc. |
Genes del receptor-1 de VEGF soluble modificado y vectores para terapia génica
|
|
WO2014143932A1
(en)
|
2013-03-15 |
2014-09-18 |
The University Of North Carolina At Chapel Hill |
Synthetic adeno-associated virus inverted terminal repeats
|
|
ES2926774T3
(es)
|
2013-03-15 |
2022-10-28 |
Univ North Carolina Chapel Hill |
Métodos y composiciones para vectores AAV de doble unión de glicano
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
WO2014168953A1
(en)
|
2013-04-08 |
2014-10-16 |
University Of Iowa Research Foundation |
Chimeric adeno-associated virus/ bocavirus parvovirus vector
|
|
EP3003391B1
(en)
|
2013-05-31 |
2021-09-22 |
The Regents of The University of California |
Adeno-associated virus variants and methods of use thereof
|
|
US20160122727A1
(en)
|
2013-06-13 |
2016-05-05 |
Shire Human Genetic Therapies, Inc. |
Messenger rna based viral production
|
|
LT3013855T
(lt)
|
2013-06-24 |
2021-01-25 |
Xiao, Weidong |
Mutavusio viii faktoriaus kompozicijos ir metodai
|
|
AU2014305218B2
(en)
|
2013-08-05 |
2020-01-16 |
Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum |
Recombinant AAV-Crumbs homologue composition and methods for treating LCA-8 and progressive RP
|
|
WO2015048534A1
(en)
|
2013-09-26 |
2015-04-02 |
University Of Florida Research Foundation, Inc. |
Synthetic combinatorial aav capsid library for targeted gene therapy
|
|
WO2015044292A1
(en)
|
2013-09-26 |
2015-04-02 |
Universitat Autonoma De Barcelona |
Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease
|
|
CN105745326A
(zh)
|
2013-10-24 |
2016-07-06 |
优尼科Ip有限公司 |
用于基因治疗神经疾病的aav-5假型载体
|
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
|
KR20230076867A
(ko)
|
2013-12-20 |
2023-05-31 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신생항원 백신과의 병용 요법
|
|
US10238700B2
(en)
|
2014-01-02 |
2019-03-26 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
|
SMT202000531T1
(it)
|
2014-03-09 |
2020-11-10 |
Univ Pennsylvania |
Composizioni utili in trattamento di deficit di ornitina transcarbamilasi(otc)
|
|
EP3800191B1
(en)
|
2014-03-17 |
2025-08-20 |
Adverum Biotechnologies, Inc. |
Compositions and methods for enhanced gene expression in cone cells
|
|
BR112016019940A2
(pt)
|
2014-03-21 |
2017-10-24 |
Univ Leland Stanford Junior |
edição de genoma sem nucleases
|
|
WO2015164723A1
(en)
|
2014-04-25 |
2015-10-29 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
|
EP3134431B1
(en)
|
2014-04-25 |
2021-04-07 |
The Trustees Of The University Of Pennsylvania |
Ldlr variants and their use in compositions for reducing cholesterol levels
|
|
ES2833230T3
(es)
|
2014-05-13 |
2021-06-14 |
Univ Pennsylvania |
Composiciones que comprenden AVV que expresan construcciones y usos de doble anticuerpo del mismo
|
|
EP3151866B1
(en)
|
2014-06-09 |
2023-03-08 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
EP3194430A1
(en)
|
2014-09-16 |
2017-07-26 |
Universitat Autònoma De Barcelona |
Adeno-associated viral vectors for the gene therapy of metabolic diseases
|
|
BR112017007765B1
(pt)
|
2014-10-14 |
2023-10-03 |
Halozyme, Inc |
Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
|
|
WO2016077687A1
(en)
|
2014-11-14 |
2016-05-19 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
EP4344741A3
(en)
|
2014-11-21 |
2024-08-28 |
The University of North Carolina at Chapel Hill |
Aav vectors targeted to the central nervous system
|
|
HUE046643T2
(hu)
*
|
2014-11-28 |
2021-11-29 |
Uniqure Ip Bv |
DNS szennyezõdések parvovirális virionokat tartalmazó készítményben
|
|
US10975442B2
(en)
|
2014-12-19 |
2021-04-13 |
Massachusetts Institute Of Technology |
Molecular biomarkers for cancer immunotherapy
|
|
EP3234130B1
(en)
|
2014-12-19 |
2020-11-25 |
The Broad Institute, Inc. |
Methods for profiling the t-cell- receptor repertoire
|
|
US11033638B2
(en)
|
2015-01-07 |
2021-06-15 |
Universität Autonoma De Barcelona |
Single-vector gene construct comprising insulin and glucokinase genes
|
|
US10907176B2
(en)
|
2015-01-14 |
2021-02-02 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for targeted gene transfer
|
|
WO2016130600A2
(en)
|
2015-02-09 |
2016-08-18 |
Duke University |
Compositions and methods for epigenome editing
|
|
US11021519B2
(en)
|
2015-03-02 |
2021-06-01 |
Adverum Biotechnologies, Inc. |
Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
|
|
EP3268044A2
(en)
|
2015-03-11 |
2018-01-17 |
The Broad Institute Inc. |
Prmt5 inhibitors for the treatment of cancer with reduced mtap activty
|
|
JP6836999B2
(ja)
|
2015-03-24 |
2021-03-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ |
アデノ随伴ウイルス変異体及びその使用方法
|
|
EP3288594B1
(en)
|
2015-04-27 |
2022-06-29 |
The Trustees of The University of Pennsylvania |
Dual aav vector system for crispr/cas9 mediated correction of human disease
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
JP6805174B2
(ja)
|
2015-05-12 |
2020-12-23 |
アメリカ合衆国 |
神経成長因子シグナルペプチド及び副甲状腺ホルモンを含むａａｖ分離株及び融合タンパク質
|
|
EA201792500A1
(ru)
|
2015-05-13 |
2018-04-30 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Aav-опосредованная экспрессия антител против гриппа и способы их использования
|
|
IL294183B2
(en)
|
2015-05-20 |
2023-10-01 |
Dana Farber Cancer Inst Inc |
shared neoantigens
|
|
TW202241500A
(zh)
|
2015-06-09 |
2022-11-01 |
美商博德研究所有限公司 |
用於贅瘤疫苗之調配物及其製備方法
|
|
US20160361380A1
(en)
|
2015-06-12 |
2016-12-15 |
Nymox Corporation |
Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
|
|
US10676735B2
(en)
|
2015-07-22 |
2020-06-09 |
Duke University |
High-throughput screening of regulatory element function with epigenome editing technologies
|
|
GB2592821B
(en)
|
2015-07-31 |
2022-01-12 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
WO2017024198A1
(en)
|
2015-08-06 |
2017-02-09 |
The Trustees Of The University Of Pennsylvania |
Glp-1 and use thereof in compositions for treating metabolic diseases
|
|
US20190000943A1
(en)
*
|
2015-08-13 |
2019-01-03 |
Aavet Therapeutics, Llc |
Aav6 vectors for immunotherapy
|
|
WO2017035416A2
(en)
|
2015-08-25 |
2017-03-02 |
Duke University |
Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
|
|
CA2995733A1
(en)
|
2015-08-31 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Aav-epo for treating companion animals
|
|
CN108291216B
(zh)
|
2015-09-24 |
2022-09-16 |
宾夕法尼亚州大学信托人 |
用于治疗补体介导的疾病的组合物和方法
|
|
ES2865487T3
(es)
|
2015-09-28 |
2021-10-15 |
Univ North Carolina Chapel Hill |
Métodos y composiciones para vectores virales que evaden los anticuerpos
|
|
US11273227B2
(en)
|
2015-10-09 |
2022-03-15 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treating Stargardt's disease and other ocular disorders
|
|
EP4089175A1
(en)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
US12188037B2
(en)
|
2015-10-22 |
2025-01-07 |
University Of Florida Research Foundation, Incorporated |
Synthetic combinatorial AAV3 capsid library
|
|
CN108779167A
(zh)
|
2015-10-28 |
2018-11-09 |
宾夕法尼亚州大学信托人 |
鞘内施用腺伴随病毒载体用于基因治疗
|
|
SG11201802408RA
(en)
|
2015-11-05 |
2018-05-30 |
Bamboo Therapeutics Inc |
Modified friedreich ataxia genes and vectors for gene therapy
|
|
KR102787119B1
(ko)
|
2015-11-30 |
2025-03-27 |
듀크 유니버시티 |
유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법
|
|
EP3384034B1
(en)
|
2015-12-02 |
2020-07-08 |
The Board of Trustees of the Leland Stanford Junior University |
Novel recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism
|
|
US10406244B2
(en)
|
2015-12-02 |
2019-09-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
AAV vectors with expanded packaging capacity
|
|
AU2016366560A1
(en)
|
2015-12-11 |
2018-06-28 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
|
JP7061067B2
(ja)
|
2015-12-14 |
2022-04-27 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
クリグラー・ナジャー症候群の処置のための組成物
|
|
JP7406783B2
(ja)
|
2015-12-14 |
2023-12-28 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
パルボウイルスベクターの高められた送達のための改変キャプシドタンパク質
|
|
CA3008264A1
(en)
|
2015-12-14 |
2017-06-22 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
|
EP3411484B1
(en)
|
2016-02-05 |
2023-10-04 |
Emory University |
Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid
|
|
WO2017139381A1
(en)
|
2016-02-08 |
2017-08-17 |
University Of Iowa Research Foundation |
Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
|
|
JP6947739B2
(ja)
|
2016-02-16 |
2021-10-13 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
既存のヒト中和抗体に対して耐性である新規組換えアデノ随伴ウイルスカプシド
|
|
CA3011943A1
(en)
|
2016-02-22 |
2017-08-31 |
The University Of North Carolina At Chapel Hill |
Aav-idua vector for treatment of mps i-associated blindness
|
|
CA3016985C
(en)
|
2016-03-07 |
2023-07-04 |
University Of Iowa Research Foundation |
Aav-mediated expression using a synthetic promoter and enhancer
|
|
JP2019513373A
(ja)
|
2016-03-31 |
2019-05-30 |
ネオン セラピューティクス， インコーポレイテッド |
ネオ抗原およびその使用方法
|
|
US20190127713A1
(en)
|
2016-04-13 |
2019-05-02 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
WO2017181152A2
(en)
|
2016-04-15 |
2017-10-19 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
MX2018012472A
(es)
|
2016-04-15 |
2019-08-12 |
Alpine Immune Sciences Inc |
Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
|
|
AU2017254477A1
(en)
|
2016-04-18 |
2018-11-01 |
Jennifer G. ABELIN |
Improved HLA epitope prediction
|
|
EP3449250B1
(en)
|
2016-04-28 |
2020-11-04 |
Indiana University Research & Technology Corporation |
Methods and compositions for resolving components of a virus preparation
|
|
US11364308B2
(en)
|
2016-05-13 |
2022-06-21 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and methods of use thereof
|
|
WO2017205739A1
(en)
|
2016-05-26 |
2017-11-30 |
University Of Iowa Research Foundation |
cis AND trans REQUIREMENTS FOR TERMINAL RESOLUTION OF HUMAN BOCAVIRUS 1
|
|
CN109415730A
(zh)
|
2016-06-13 |
2019-03-01 |
北卡罗来纳大学教堂山分校 |
优化的cln1基因和表达盒以及它们的应用
|
|
US10183058B2
(en)
|
2016-06-17 |
2019-01-22 |
Nymox Corporation |
Method of preventing or reducing the progression of prostate cancer
|
|
CA2971303C
(en)
|
2016-06-21 |
2026-03-03 |
Bamboo Therapeutics, Inc. |
Optimized mini-dystrophin genes and expression cassettes and their use
|
|
WO2018009814A1
(en)
|
2016-07-08 |
2018-01-11 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treatment of disorders and diseases involving rdh12
|
|
JP7490211B2
(ja)
|
2016-07-19 |
2024-05-27 |
デューク ユニバーシティ |
Ｃｐｆ１に基づくゲノム編集の治療適用
|
|
WO2018022511A1
(en)
|
2016-07-25 |
2018-02-01 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
|
BR112019001344A2
(pt)
|
2016-07-26 |
2019-04-30 |
The University Of North Carolina At Chapel Hill |
tolerância imunológica mediada por vetor no olho
|
|
WO2018022945A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd112 variant immunomodulatory proteins and uses thereof
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
WO2018022946A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
US10172910B2
(en)
|
2016-07-28 |
2019-01-08 |
Nymox Corporation |
Method of preventing or reducing the incidence of acute urinary retention
|
|
AU2017302013B2
(en)
|
2016-07-29 |
2022-05-26 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
EP4485466A3
(en)
*
|
2016-08-17 |
2025-04-02 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
WO2018035387A1
(en)
*
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
IL315358A
(en)
|
2016-08-18 |
2024-11-01 |
Univ California |
CRISPR-CAS genome engineering using a modular AAV delivery system
|
|
JP7165410B2
(ja)
|
2016-08-19 |
2022-11-04 |
ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド |
組換え自己相補的アデノ随伴ウイルスを使用して疾患を治療するための方法及び組成物
|
|
US10532081B2
(en)
|
2016-09-07 |
2020-01-14 |
Nymox Corporation |
Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
|
|
CA3040179A1
(en)
|
2016-10-19 |
2018-04-26 |
Adverum Biotechnologies, Inc. |
Modified aav capsids and uses thereof
|
|
WO2018075978A1
(en)
|
2016-10-20 |
2018-04-26 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
US20190328846A1
(en)
|
2016-12-01 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical compositions for the treatment of retinal degenerative diseases
|
|
KR20190088561A
(ko)
|
2016-12-07 |
2019-07-26 |
유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 |
인터류킨-1 수용체 길항제(IL-1RA) cDNA
|
|
US11142775B2
(en)
|
2017-01-13 |
2021-10-12 |
University Of Iowa Research Foundation |
Bocaparvovirus small noncoding RNA and uses thereof
|
|
US11549149B2
(en)
|
2017-01-24 |
2023-01-10 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
|
CN110546265A
(zh)
|
2017-02-09 |
2019-12-06 |
因达普塔治疗公司 |
工程化自然杀伤(nk)细胞及其组合物和方法
|
|
US11965892B2
(en)
|
2017-02-12 |
2024-04-23 |
Biontech Us Inc. |
HLA-based methods and compositions and uses thereof
|
|
US11905312B2
(en)
*
|
2017-02-15 |
2024-02-20 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for gene transfer across the vasculature
|
|
JP2020510648A
(ja)
|
2017-02-20 |
2020-04-09 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
家族性高コレステロール血症を処置するための遺伝子治療
|
|
EP3585883A4
(en)
|
2017-02-21 |
2021-04-14 |
University of Florida Research Foundation, Incorporated |
MODIFIED AAV CAPSID PROTEINS AND USES THEREOF
|
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
UY37620A
(es)
|
2017-02-28 |
2018-08-31 |
Univ Pennsylvania |
Vacunas contra la gripe mediadas por aav novedosas
|
|
PT3589730T
(pt)
|
2017-02-28 |
2024-02-28 |
Univ Pennsylvania |
Vetor de vírus adenoassociado (aav) de clado f e suas utilizações
|
|
RU2019130004A
(ru)
|
2017-03-01 |
2021-04-01 |
Зе Трастис Оф Зе Юниверсити Оф Пеннсильвания |
Генная терапия при глазных заболеваниях
|
|
US10335453B2
(en)
|
2017-03-01 |
2019-07-02 |
Nymox Corporation |
Compositions and methods for improving sexual function
|
|
US10550405B2
(en)
|
2017-03-15 |
2020-02-04 |
The University Of North Carolina At Chapel Hill |
Rational polyploid adeno-associated virus vectors and methods of making and using the same
|
|
NZ756587A
(en)
|
2017-03-15 |
2025-12-19 |
Univ North Carolina Chapel Hill |
Polyploid adeno-associated virus vectors and methods of making and using the same
|
|
SG11201907769XA
(en)
|
2017-03-16 |
2019-09-27 |
Alpine Immune Sciences Inc |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
KR20190141146A
(ko)
|
2017-03-16 |
2019-12-23 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Pd-l2 변이체 면역조절 단백질 및 그의 용도
|
|
EP3596116B1
(en)
|
2017-03-16 |
2023-09-06 |
Alpine Immune Sciences, Inc. |
Pd-l1 variant immunomodulatory proteins and uses thereof
|
|
WO2018195555A1
(en)
|
2017-04-21 |
2018-10-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Crispr/cas 9-mediated integration of polynucleotides by sequential homologous recombination of aav donor vectors
|
|
WO2018200542A1
(en)
|
2017-04-24 |
2018-11-01 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
|
IL316926A
(en)
|
2017-05-11 |
2025-01-01 |
Univ Pennsylvania |
Gene therapy for neuronal ceroid lipofuscinosis
|
|
EP3625344A1
(en)
|
2017-05-15 |
2020-03-25 |
University of Florida Research Foundation, Inc. |
Core master regulators of glioblastoma stem cells
|
|
IL270882B2
(en)
|
2017-05-24 |
2024-02-01 |
Univ Barcelona Autonoma |
Viral expression vectors containing the coding sequence for FIBROBLAST GROWTH FACTOR 21 (FGF21
|
|
EP3630160A1
(en)
|
2017-05-24 |
2020-04-08 |
Universitat Autònoma De Barcelona |
Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence
|
|
EP3630986B1
(en)
|
2017-05-31 |
2026-03-25 |
The Trustees of The University of Pennsylvania |
Gene therapy for treating peroxisomal disorders
|
|
JP7766393B2
(ja)
|
2017-06-14 |
2025-11-10 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
眼疾患のための遺伝子療法
|
|
EP3645021A4
(en)
*
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
CA3053154A1
(en)
|
2017-06-30 |
2019-01-03 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsids and methods of use thereof
|
|
JP7764129B2
(ja)
|
2017-07-10 |
2025-11-05 |
ユニキュアー アイピー ビー．ブイ． |
ヒトにおけるａａｖ遺伝子療法のための手段及び方法
|
|
EP3808849A1
(en)
|
2017-08-03 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
NZ762100A
(en)
|
2017-08-09 |
2025-12-19 |
Bioverativ Therapeutics Inc |
Nucleic acid molecules and uses thereof
|
|
JP2020534788A
(ja)
|
2017-08-28 |
2020-12-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
アデノ随伴ウイルスカプシド変異体及びその使用方法
|
|
EP3676284A1
(en)
*
|
2017-08-29 |
2020-07-08 |
Ruprecht-Karls-Universität Heidelberg |
Rationally designed virus-like particles for modulation of chimeric antigen receptor (car)-t-cell therapy
|
|
WO2019060538A1
(en)
|
2017-09-20 |
2019-03-28 |
The Trustees Of Indiana University |
METHODS FOR LIPOPROTEIN RESOLUTION BY MASS SPECTROMETRY
|
|
RU2770922C2
(ru)
|
2017-09-20 |
2022-04-25 |
4Д Молекьюлар Терапьютикс Инк. |
Капсиды вариантов аденоассоциированных вирусов и методы их применения
|
|
AU2018346104B2
(en)
|
2017-10-03 |
2023-07-27 |
Prevail Therapeutics, Inc. |
Gene therapies for lysosomal disorders
|
|
BR112020006661A2
(pt)
|
2017-10-03 |
2020-10-13 |
Prevail Therapeutics, Inc. |
terapias de genes para distúrbios lipossomais
|
|
CN112501208A
(zh)
|
2017-10-03 |
2021-03-16 |
普利维尔治疗公司 |
用于溶酶体障碍的基因疗法
|
|
JP7749319B2
(ja)
|
2017-10-10 |
2025-10-06 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
|
|
US12043848B2
(en)
|
2017-10-16 |
2024-07-23 |
Vigeneron Gmbh |
AAV vectors
|
|
EP3697908A1
(en)
|
2017-10-16 |
2020-08-26 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
TW202413649A
(zh)
|
2017-10-16 |
2024-04-01 |
美商航海家醫療公司 |
肌萎縮性脊髓側索硬化症(als)之治療
|
|
BR112020007542A2
(pt)
|
2017-10-18 |
2020-12-01 |
Alpine Immune Sciences, Inc. |
proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados
|
|
RU2020118342A
(ru)
|
2017-11-07 |
2021-12-08 |
Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл |
Оптимизированные гены aga и экспрессионные кластеры и их применение
|
|
CN111770999A
(zh)
|
2017-11-27 |
2020-10-13 |
4D分子治疗有限公司 |
腺相关病毒变体衣壳和用于抑制血管生成的应用
|
|
US10538571B2
(en)
|
2017-11-27 |
2020-01-21 |
Coda Biotherapeutics, Inc. |
Compositions and methods for neurological diseases
|
|
TW201930340A
(zh)
|
2017-12-18 |
2019-08-01 |
美商尼恩醫療公司 |
新抗原及其用途
|
|
EP3727468A4
(en)
|
2017-12-19 |
2021-09-22 |
Akouos, Inc. |
AAV-MEDIATED THERAPEUTIC ANTIBODIES DELIVERY TO THE INTERNAL EAR
|
|
AU2019205273B2
(en)
|
2018-01-03 |
2024-04-04 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
EP3738137A1
(en)
|
2018-01-12 |
2020-11-18 |
The Trustees of Indiana University |
Electrostatic linear ion trap design for charge detection mass spectrometry
|
|
EP3740580A4
(en)
|
2018-01-19 |
2021-10-20 |
Duke University |
GENOME ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYONTS
|
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
|
US20190256867A1
(en)
|
2018-02-01 |
2019-08-22 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring pah gene function and methods of use thereof
|
|
JP7244547B2
(ja)
|
2018-02-19 |
2023-03-22 |
ホモロジー・メディシンズ・インコーポレイテッド |
Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法
|
|
EP3768695A4
(en)
|
2018-02-27 |
2022-04-06 |
The Trustees of the University of Pennsylvania |
NOVEL ADENO-ASSOCIATED VIRUS (AAV) VECTORS, AAV VECTORS WITH REDUCED CAPSIID DEAMIDATION AND USES THEREOF
|
|
EP3759218A4
(en)
|
2018-02-28 |
2021-12-08 |
The University of North Carolina at Chapel Hill |
PROCEDURES AND COMPOSITIONS FOR ANTIBODY ELIMINATING VIRUS VECTORS
|
|
CA3092871A1
(en)
*
|
2018-03-06 |
2019-09-12 |
University Of Florida Research Foundation, Incorporated |
Aav chimeras
|
|
EP3774853A1
(en)
|
2018-03-30 |
2021-02-17 |
The Board of Trustees of the Leland Stanford Junior University |
Novel recombinant adeno-associated virus capsids with enhanced human pancreatic tropism
|
|
EP3774852A1
(en)
|
2018-04-03 |
2021-02-17 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
|
MX2020010465A
(es)
|
2018-04-03 |
2021-01-08 |
|
Vectores de virus para direccionamiento a tejidos oftalmicos.
|
|
AU2019247748A1
(en)
|
2018-04-03 |
2020-10-08 |
Ginkgo Bioworks, Inc. |
Antibody-evading virus vectors
|
|
CA3095911A1
(en)
*
|
2018-04-03 |
2019-10-10 |
Cornell University |
Gene therapy for oxidative stress
|
|
CA3097192A1
(en)
|
2018-04-27 |
2019-10-31 |
Voyager Therapeutics, Inc. |
Methods for measuring the potency of aadc viral vectors
|
|
US12215338B2
(en)
|
2018-05-08 |
2025-02-04 |
Neuracle Science Co., Ltd. |
Adeno-associated virus (AAV) delivery of anti-FAM19A5 antibodies
|
|
WO2019222329A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
KR20210019996A
(ko)
|
2018-05-15 |
2021-02-23 |
보이저 테라퓨틱스, 인크. |
파킨슨병의 치료를 위한 조성물 및 방법
|
|
US11821009B2
(en)
|
2018-05-15 |
2023-11-21 |
Cornell University |
Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery
|
|
US20210214749A1
(en)
|
2018-05-16 |
2021-07-15 |
Voyager Therapeutics, Inc. |
Directed evolution
|
|
US20210207167A1
(en)
|
2018-05-16 |
2021-07-08 |
Voyager Therapeutics, Inc. |
Aav serotypes for brain specific payload delivery
|
|
CA3100838A1
(en)
|
2018-06-04 |
2019-12-12 |
The Trustees Of Indiana University |
Charge detection mass spectrometry with real time analysis and signal optimization
|
|
WO2019236143A1
(en)
|
2018-06-04 |
2019-12-12 |
The Trustees Of Indiana University |
Apparatus and method for calibrating or resetting a charge detector
|
|
WO2019236139A1
(en)
|
2018-06-04 |
2019-12-12 |
The Trustees Of Indiana University |
Interface for transporting ions from an atmospheric pressure environment to a low pressure environment
|
|
JP7398810B2
(ja)
|
2018-06-04 |
2023-12-15 |
ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー |
静電線形イオン・トラップにイオンを捕獲する装置および方法
|
|
EA202000353A1
(ru)
|
2018-06-04 |
2022-01-14 |
Калиди Биотерапьютикс, Инк. |
Основанные на клетках носители для потенциализации вирусной терапии
|
|
EP4391015A3
(en)
|
2018-06-04 |
2024-10-09 |
The Trustees of Indiana University |
Ion trap array for high throughput charge detection mass spectrometry
|
|
US11505782B2
(en)
|
2018-06-04 |
2022-11-22 |
Calidi Biotherapeutics, Inc. |
Cell-based vehicles for potentiation of viral therapy
|
|
AU2019287468B2
(en)
|
2018-06-12 |
2024-10-10 |
The University Of North Carolina At Chapel Hill |
Synthetic liver-tropic adeno-associated virus capsids and uses thereof
|
|
WO2019241486A1
(en)
|
2018-06-13 |
2019-12-19 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
|
BR112020025268A2
(pt)
|
2018-06-28 |
2021-03-09 |
The University Of North Carolina At Chapel Hill |
Cassetes de expressão e genes cln5 otimizados e seu uso
|
|
WO2020010035A1
(en)
|
2018-07-02 |
2020-01-09 |
Voyager Therapeutics, Inc. |
Cannula system
|
|
US20210254103A1
(en)
|
2018-07-02 |
2021-08-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
|
|
CN112770812A
(zh)
|
2018-07-24 |
2021-05-07 |
沃雅戈治疗公司 |
产生基因治疗制剂的系统和方法
|
|
WO2020028751A2
(en)
|
2018-08-03 |
2020-02-06 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
EP3833766A1
(en)
*
|
2018-08-09 |
2021-06-16 |
Bioverativ Therapeutics Inc. |
Nucleic acid molecules and uses thereof for non-viral gene therapy
|
|
IL280300B2
(en)
|
2018-08-10 |
2025-06-01 |
Univ North Carolina Chapel Hill |
Optimized cln7 genes and expression cassettes and their use
|
|
US20200061150A1
(en)
|
2018-08-23 |
2020-02-27 |
Nymox Corporation |
Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
|
|
US11242528B2
(en)
|
2018-08-28 |
2022-02-08 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
EP3856762A1
(en)
|
2018-09-28 |
2021-08-04 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
CA3114175A1
(en)
|
2018-10-01 |
2020-04-09 |
The Trustees Of The University Of Pennsylvania |
Beta-galactosidase based aav for treating gm1 gangliosidosis
|
|
CN113166208B
(zh)
|
2018-10-02 |
2024-11-22 |
沃雅戈治疗公司 |
重新定向aav衣壳的嗜性
|
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
WO2020072849A1
(en)
|
2018-10-04 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
WO2020072844A1
(en)
|
2018-10-05 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
CN113166781A
(zh)
|
2018-10-15 |
2021-07-23 |
沃雅戈治疗公司 |
在杆状病毒/Sf9系统中大规模生产rAAV的表达载体
|
|
JP2022506066A
(ja)
|
2018-11-05 |
2022-01-17 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
最適化されたｆｉｇ４遺伝子および発現カセットならびにそれらの使用
|
|
CA3116192C
(en)
|
2018-11-06 |
2025-09-23 |
Calidi Biotherapeutics (Nevada), Inc. |
IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY
|
|
CN113574632B
(zh)
|
2018-11-20 |
2024-07-30 |
印地安纳大学理事会 |
用于单粒子质谱分析的轨道阱
|
|
EP3884041A2
(en)
|
2018-11-21 |
2021-09-29 |
Indapta Therapeutics, Inc. |
Methods for expansion of natural killer (nk) cell subset and related compositions and methods
|
|
CA3120923A1
(en)
|
2018-11-26 |
2020-06-04 |
Universitat Autonoma De Barcelona |
Fibroblast growth factor 21 (fgf21) gene therapy
|
|
CA3120868A1
(en)
|
2018-11-30 |
2020-06-04 |
Alpine Immune Sciences, Inc. |
Cd86 variant immunomodulatory proteins and uses thereof
|
|
EP4443473A3
(en)
|
2018-12-03 |
2025-01-01 |
The Trustees of Indiana University |
Apparatus for simultaneously analyzing multiple ions with an electrostatic linear ion trap
|
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
SG11202106356QA
(en)
|
2018-12-20 |
2021-07-29 |
Vigeneron Gmbh |
An optimized acceptor splice site module for biological and biotechnological applications
|
|
WO2020132385A1
(en)
|
2018-12-21 |
2020-06-25 |
The University Of North Carolina At Chapel Hill |
Optimized galc genes and expression cassettes and their use
|
|
KR20240091046A
(ko)
|
2018-12-21 |
2024-06-21 |
바이오엔테크 유에스 인크. |
Hla 클래스 ii-특이적 에피토프 예측 및 cd4+ t 세포 특징화를 위한 방법 및 시스템
|
|
SG11202107645RA
(en)
|
2019-01-18 |
2021-08-30 |
Voyager Therapeutics Inc |
Methods and systems for producing aav particles
|
|
WO2020160508A1
(en)
|
2019-01-31 |
2020-08-06 |
Oregon Health & Science University |
Methods for using transcription-dependent directed evolution of aav capsids
|
|
CN113728108A
(zh)
|
2019-02-15 |
2021-11-30 |
桑格摩生物治疗股份有限公司 |
用于生产重组aav的组合物和方法
|
|
BR112021015817A2
(pt)
|
2019-02-22 |
2021-10-13 |
The Trustees Of The University Of Pennsylvania |
Vírus adeno-associado recombinante para tratamento de neurodegeneração com início na idade adulta associado a grn
|
|
SG11202108044YA
(en)
|
2019-02-25 |
2021-09-29 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
US20220154211A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
EP3931337A1
(en)
|
2019-02-26 |
2022-01-05 |
The Trustees of The University of Pennsylvania |
Compositions useful in treatment of krabbe disease
|
|
US12024709B2
(en)
|
2019-02-27 |
2024-07-02 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
|
JP2022524951A
(ja)
|
2019-02-27 |
2022-05-11 |
アクティム・セラピューティクス・インコーポレイテッド |
腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌
|
|
CN113795279B
(zh)
|
2019-03-04 |
2024-12-31 |
宾夕法尼亚州大学信托人 |
靶向akt通路的神经保护性基因疗法
|
|
AR118465A1
(es)
|
2019-03-21 |
2021-10-06 |
Stridebio Inc |
Vectores de virus adenoasociados recombinantes
|
|
JP7664848B2
(ja)
|
2019-04-10 |
2025-04-18 |
プリベイル セラピューティクス，インコーポレーテッド |
リソソーム障害のための遺伝子療法
|
|
EP3959741A1
(en)
|
2019-04-23 |
2022-03-02 |
The Trustees of Indiana University |
Identification of sample subspecies based on particle charge behavior under structural change-inducing sample conditions
|
|
EP4169535A1
(en)
|
2019-04-26 |
2023-04-26 |
The University of North Carolina at Chapel Hill |
Methods and compositions for dual glycan binding aav2.5 vector
|
|
WO2020223215A1
(en)
|
2019-04-29 |
2020-11-05 |
The University Of North Carolina At Chapel Hill |
Optimized sumf1 genes and expression cassettes and their use
|
|
WO2020223280A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
EP3962536A1
(en)
|
2019-04-29 |
2022-03-09 |
Voyager Therapeutics, Inc. |
Systems and methods for producing baculoviral infected insect cells (biics) in bioreactors
|
|
KR20220020261A
(ko)
|
2019-05-03 |
2022-02-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
이염성 백질이영양증의 치료에 유용한 조성물
|
|
US20240124889A1
(en)
|
2019-05-07 |
2024-04-18 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
US11278588B2
(en)
|
2019-05-13 |
2022-03-22 |
Nymox Corporation |
Method of treating lower urinary tract symptoms with fexapotide triflutate
|
|
US11298400B2
(en)
|
2019-05-13 |
2022-04-12 |
Nymox Corporation |
Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
|
|
US12465655B2
(en)
|
2019-05-22 |
2025-11-11 |
The University Of North Carolina At Chapel Hill |
UBE3A genes and expression cassettes and their use
|
|
WO2020239995A1
(en)
|
2019-05-31 |
2020-12-03 |
Universitat Autònoma De Barcelona |
Insulin gene therapy
|
|
EP3990030A1
(en)
|
2019-06-27 |
2022-05-04 |
Pfizer Inc. |
Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
|
|
ES2948620T3
(es)
|
2019-07-10 |
2023-09-14 |
Masonic Medical Res Laboratory |
Vgll4 con elemento regulador CIS de UCP-1 y método de uso del mismo
|
|
EP4007814A1
(en)
|
2019-07-26 |
2022-06-08 |
Akouos, Inc. |
Methods of treating hearing loss using a secreted target protein
|
|
US11231421B2
(en)
|
2019-07-31 |
2022-01-25 |
Nymox Corporation |
Methods of treating multifocal cancer
|
|
US11331374B2
(en)
|
2019-07-31 |
2022-05-17 |
Nymox Corporation |
Focal treatment of prostate cancer
|
|
WO2021025995A1
(en)
|
2019-08-02 |
2021-02-11 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
EP4010465A1
(en)
|
2019-08-09 |
2022-06-15 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
CA3146702A1
(en)
*
|
2019-08-09 |
2021-02-18 |
Sergei Zolotukhin |
Aav capsid variants for targeting human glioblastoma cells
|
|
AU2020334147A1
(en)
|
2019-08-21 |
2022-03-31 |
Trames Bio, Inc. |
Compositions and methods for neurological diseases
|
|
EP4022070A1
(en)
|
2019-08-26 |
2022-07-06 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
CN111454969B
(zh)
*
|
2019-09-02 |
2022-08-26 |
西北农林科技大学 |
带有双标签猪细小病毒全长感染性克隆制备方法及应用
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
WO2021061650A1
(en)
|
2019-09-25 |
2021-04-01 |
The Trustees Of Indiana University |
Apparatus and method for pulsed mode charge detection mass spectrometry
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
CN114728237B
(zh)
|
2019-10-10 |
2026-02-24 |
印地安纳大学理事会 |
用于识别、选择和纯化粒子的系统和方法
|
|
JP2022551739A
(ja)
|
2019-10-17 |
2022-12-13 |
ストライドバイオ，インコーポレイテッド |
ニーマン・ピック病ｃ型の治療のためのアデノ随伴ウイルスベクター
|
|
US12611436B2
(en)
|
2019-10-17 |
2026-04-28 |
Sarepta Therapeutics, Inc. |
AAV transfer cassette
|
|
WO2021080975A1
(en)
*
|
2019-10-21 |
2021-04-29 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for reducing cholesterol levels
|
|
AU2020401116A1
(en)
|
2019-12-10 |
2022-07-21 |
Takeda Pharmaceutical Company Limited |
Adeno associated virus vectors for the treatment of Hunter disease
|
|
EP4077684A1
(en)
*
|
2019-12-18 |
2022-10-26 |
Genethon |
Production of recombinant viral vectors from plant hairy roots
|
|
JP7690209B2
(ja)
|
2019-12-18 |
2025-06-10 |
ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー |
電荷測定装置を有する質量分析計
|
|
CA3162020A1
(en)
|
2019-12-19 |
2021-06-24 |
James M. Wilson |
Compositions for treating friedreich's ataxia
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
EP4100991B1
(en)
|
2020-02-03 |
2025-01-29 |
The Trustees of Indiana University |
A charge detection mass spectrometer and related method
|
|
EP4100056A4
(en)
*
|
2020-02-07 |
2024-03-06 |
Vecprobio, Inc. |
Recombinant adeno-associated viral vectors in plants
|
|
US20210284699A1
(en)
*
|
2020-03-12 |
2021-09-16 |
California Institute Of Technology |
Adeno-associated viral capsids with expanded sizes
|
|
US12605465B2
(en)
|
2020-03-23 |
2026-04-21 |
The University Of North Carolina At Chapel Hill |
AAV-NAGLU vectors for treatment of mucopolysaccharidosis IIIB
|
|
WO2021202651A1
(en)
|
2020-04-01 |
2021-10-07 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
JP7713956B2
(ja)
|
2020-04-15 |
2025-07-28 |
ボイジャー セラピューティクス インコーポレイテッド |
タウ結合化合物
|
|
GB202005732D0
(en)
|
2020-04-20 |
2020-06-03 |
Synpromics Ltd |
Regulatory nucleic acid sequences
|
|
AU2021258194A1
(en)
|
2020-04-22 |
2022-11-24 |
Indapta Therapeutics, Inc. |
Natural killer (NK) cell compositions and methods for generating same
|
|
CA3177869A1
(en)
|
2020-05-05 |
2021-11-11 |
Duke University |
Cross-species compatible adeno-associated virus compositions and methods of use thereof
|
|
JP2023524577A
(ja)
|
2020-05-05 |
2023-06-12 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
改変アデノ随伴ウイルス５カプシドおよびその使用
|
|
EP4146684A2
(en)
|
2020-05-08 |
2023-03-15 |
Alpine Immune Sciences, Inc. |
April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
|
|
IL298128A
(en)
|
2020-05-13 |
2023-01-01 |
Akouos Inc |
Compositions and methods for treating slc26a4-associated hearing loss
|
|
TWI900553B
(zh)
|
2020-05-13 |
2025-10-11 |
美商航海家醫療公司 |
Aav蛋白殼之趨性重定向
|
|
KR20230017845A
(ko)
|
2020-05-26 |
2023-02-06 |
유니버시타트 아우토노마 데 바르셀로나 |
중추 신경계 장애에 대한 섬유아세포 성장 인자 21(fgf21) 유전자 요법
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
CN111778219A
(zh)
*
|
2020-07-08 |
2020-10-16 |
中国农业科学院兰州兽医研究所 |
展示南非2型口蹄疫病毒b细胞表位猪细小病毒样颗粒的制备方法
|
|
CA3186207A1
(en)
|
2020-07-23 |
2022-01-27 |
Rachel BAILEY |
Optimized slc13a5 genes and expression cassettes and their use
|
|
WO2022026410A2
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
BR112023001456A2
(pt)
|
2020-07-27 |
2023-04-11 |
Voyager Therapeutics Inc |
Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
|
|
WO2022032153A1
(en)
|
2020-08-06 |
2022-02-10 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
AU2021328475A1
(en)
|
2020-08-19 |
2023-03-16 |
Sarepta Therapeutics, Inc. |
Adeno-associated virus vectors for treatment of Rett syndrome
|
|
CA3190399A1
(en)
|
2020-08-24 |
2022-03-03 |
James M. Wilson |
Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
|
|
EP4204014A1
(en)
|
2020-08-26 |
2023-07-05 |
The Trustees of The University of Pennsylvania |
Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
|
|
GB202013940D0
(en)
|
2020-09-04 |
2020-10-21 |
Synpromics Ltd |
Regulatory nucleic acid sequences
|
|
AU2021358781A1
(en)
|
2020-10-07 |
2023-05-18 |
Tern Therapeutics, Llc |
Gene therapy for ocular manifestations of cln2 disease
|
|
CA3195177A1
(en)
|
2020-10-07 |
2022-04-14 |
Asklepios Biopharmaceutical, Inc. |
Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i)
|
|
WO2022082109A1
(en)
|
2020-10-18 |
2022-04-21 |
The Trustees Of The University Of Pennsylvania |
Improved adeno-associated virus (aav) vector and uses therefor
|
|
WO2022093769A1
(en)
|
2020-10-28 |
2022-05-05 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for dual glycan binding aav2.5 vector
|
|
WO2022094078A1
(en)
|
2020-10-28 |
2022-05-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of rett syndrome
|
|
CN116490514A
(zh)
|
2020-10-28 |
2023-07-25 |
北卡罗来纳-查佩尔山大学 |
用于双重聚糖结合aav2.5载体的方法和组合物
|
|
JP2023550581A
(ja)
|
2020-10-29 |
2023-12-04 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Ａａｖカプシド及びそれを含有する組成物
|
|
AU2021375404A1
(en)
|
2020-11-03 |
2023-06-08 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
|
TW202237850A
(zh)
|
2020-12-01 |
2022-10-01 |
賓州大學委員會 |
具有組織特異性靶向基序的新穎構成物及含有其之組成物
|
|
IL303317A
(en)
|
2020-12-01 |
2023-07-01 |
Akouos Inc |
ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
|
|
JP2024501482A
(ja)
|
2020-12-14 |
2024-01-12 |
ビオンテック ユーエス インコーポレイテッド |
がん免疫療法のための組織特異的抗原
|
|
US20240052322A1
(en)
|
2020-12-15 |
2024-02-15 |
Pfizer Inc. |
HILIC UPLC-MS Method For Separating and Analyzing Intact Adeno-Associated Virus Capsid Proteins
|
|
IL303959A
(en)
|
2020-12-23 |
2023-08-01 |
Pfizer |
Methods for purification of aav vectors by affinity chromatography
|
|
IL304006A
(en)
|
2020-12-29 |
2023-08-01 |
Akouos Inc |
Compositions and methods for treating hearing loss and/or vision loss associated with CLRN1
|
|
WO2022147480A1
(en)
|
2020-12-30 |
2022-07-07 |
Ansun Biopharma, Inc. |
Oncolytic virus encoding sialidase and multispecific immune cell engager
|
|
TW202242124A
(zh)
|
2021-01-14 |
2022-11-01 |
美商史崔德生物公司 |
靶向ｔ細胞之ａａｖ載體
|
|
US20250345463A1
(en)
|
2021-01-30 |
2025-11-13 |
Universitat Autònoma De Barcelona |
Gene therapy for monogenic diabetes
|
|
WO2022165313A1
(en)
|
2021-02-01 |
2022-08-04 |
Regenxbio Inc. |
Gene therapy for neuronal ceroid lipofuscinoses
|
|
AR124981A1
(es)
|
2021-02-26 |
2023-05-24 |
Takeda Pharmaceuticals Co |
Composición y métodos para el tratamiento de la enfermedad de fabry
|
|
WO2022187548A1
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
WO2022187473A2
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
US11795207B2
(en)
|
2021-03-30 |
2023-10-24 |
AAVnerGene Inc. |
Modified plasma clotting factor VIII and method of use thereof
|
|
WO2022211791A1
(en)
|
2021-03-30 |
2022-10-06 |
AAVnerGene Inc. |
Modified plasma clotting factor viii and method of use thereof
|
|
US20240307553A1
(en)
|
2021-04-01 |
2024-09-19 |
Pfizer Inc. |
Pharmaceutical compositions containing adeno-associated viral vector
|
|
IL307633A
(en)
|
2021-04-12 |
2023-12-01 |
Univ Pennsylvania |
Useful preparations in the treatment of spinal muscular atrophy (SBMA)
|
|
WO2022221529A1
(en)
|
2021-04-16 |
2022-10-20 |
Asklepios Biopharmaceutical, Inc. |
Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
|
|
US20240181084A1
(en)
|
2021-04-23 |
2024-06-06 |
University Of Rochester |
Genome Editing by Directed Non-Homologous DNA Insertion Using a Retroviral Integrase-Cas Fusion Protein and Methods of Treatment
|
|
US20250188126A1
(en)
|
2021-04-26 |
2025-06-12 |
Alexion Pharma International Operations Limited |
Adeno-associated viral vector capsids with improved tissue tropism
|
|
EP4089171A1
(en)
|
2021-05-12 |
2022-11-16 |
Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Recombinant tert-encoding viral genomes and vectors
|
|
US20240252679A1
(en)
|
2021-05-28 |
2024-08-01 |
Shanghai Regenelead Therapies Co., Ltd. |
Recombinant adeno-associated virus having variant capsid, and application thereof
|
|
CN117836010A
(zh)
|
2021-06-21 |
2024-04-05 |
优尼科生物制药有限公司 |
改进的裂解程序
|
|
WO2022269466A1
(en)
|
2021-06-22 |
2022-12-29 |
Pfizer Inc. |
Production of adeno-associated virus vector in insect cells
|
|
KR20240107201A
(ko)
|
2021-08-31 |
2024-07-08 |
스카우트 바이오, 인코포레이티드 |
항원-결합 분자 및 이의 용도
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
JP2024537775A
(ja)
|
2021-09-30 |
2024-10-16 |
アコーオス インコーポレイテッド |
Ｋｃｎｑ４関連難聴を治療するための組成物及び方法
|
|
EP4409010A1
(en)
|
2021-10-02 |
2024-08-07 |
The Trustees of The University of Pennsylvania |
Novel aav capsids and compositions containing same
|
|
CA3234809A1
(en)
|
2021-10-20 |
2023-04-27 |
Steven Goldman |
Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss
|
|
EP4426331A1
(en)
|
2021-11-02 |
2024-09-11 |
University of Rochester |
Tcf7l2 mediated remyelination in the brain
|
|
EP4426716A1
(en)
|
2021-11-02 |
2024-09-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
US20250049955A1
(en)
|
2021-11-17 |
2025-02-13 |
Voyager Therapeutics, Inc. |
Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
EP4433169A1
(en)
|
2021-11-17 |
2024-09-25 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
TW202325850A
(zh)
|
2021-11-29 |
2023-07-01 |
大陸商上海瑞宏迪醫藥有限公司 |
Aadc、gdnf多核苷酸及其用於治療帕金森病
|
|
WO2023114816A1
(en)
|
2021-12-14 |
2023-06-22 |
Neurogene, Inc. |
Recombinant optimized galc constructs and methods for treating galc-associated disorders
|
|
WO2023111580A1
(en)
|
2021-12-16 |
2023-06-22 |
University Of Dundee |
Targeted degradation of alpha-synuclein
|
|
WO2023133574A1
(en)
|
2022-01-10 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for treatment of c9orf72-mediated disorders
|
|
CN119317718A
(zh)
|
2022-01-25 |
2025-01-14 |
宾夕法尼亚州大学信托人 |
用于改善心脏转导和肝脏去靶向的aav衣壳
|
|
WO2023147374A2
(en)
|
2022-01-25 |
2023-08-03 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
|
GB202201242D0
(en)
|
2022-01-31 |
2022-03-16 |
Univ Edinburgh |
Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
|
|
TW202342525A
(zh)
|
2022-02-02 |
2023-11-01 |
美商阿科奧斯公司 |
用於治療前庭神經鞘瘤相關症狀之抗ｖｅｇｆ抗體構築體及相關方法
|
|
TW202342759A
(zh)
|
2022-02-04 |
2023-11-01 |
美商史崔德生物公司 |
重組腺相關病毒載體及其使用方法
|
|
CA3249551A1
(en)
|
2022-02-08 |
2023-08-17 |
Voyager Therapeutics, Inc. |
AAV Capsid Variants and Their Uses
|
|
GB202201713D0
(en)
|
2022-02-10 |
2022-03-30 |
Univ Dundee |
An affinity directed phosphatase system for targeted protein dephosphorylation
|
|
AU2023220237A1
(en)
|
2022-02-21 |
2024-08-15 |
Shanghai Regenelead Therapies Co., Ltd |
Vegf-binding molecule and pharmaceutical use thereof
|
|
CN114657152A
(zh)
*
|
2022-03-31 |
2022-06-24 |
苏州博腾生物制药有限公司 |
一种新型aav血清型及其制备方法
|
|
CN119301262A
(zh)
|
2022-04-01 |
2025-01-10 |
武田药品工业株式会社 |
用于具有cns表现的疾病的基因疗法
|
|
EP4504797A1
(en)
|
2022-04-06 |
2025-02-12 |
The Trustees of The University of Pennsylvania |
Compositions and methods for treating her2 positive metastatic breast cancer and other cancers
|
|
KR20250018169A
(ko)
|
2022-04-29 |
2025-02-04 |
브로드윙 바이오 엘엘씨 |
이중특이적 항체 및 안구 질환의 치료 방법
|
|
GB202206336D0
(en)
|
2022-04-29 |
2022-06-15 |
Univ Edinburgh |
Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
|
|
US20250296996A1
(en)
|
2022-04-29 |
2025-09-25 |
Broadwing Bio, Inc. |
Angiopoietin-related protein 7-specific antibodies and uses thereof
|
|
EP4514844A1
(en)
|
2022-04-29 |
2025-03-05 |
Broadwing Bio LLC |
Complement factor h related 4-specific antibodies and uses thereof
|
|
WO2023220040A1
(en)
*
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified capsid for gene therapy
|
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
EP4532515A1
(en)
|
2022-06-02 |
2025-04-09 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
EP4543473A1
(en)
|
2022-06-22 |
2025-04-30 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
IL317874A
(en)
|
2022-06-24 |
2025-02-01 |
Tune Therapeutics Inc |
Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression
|
|
CA3259902A1
(en)
|
2022-06-28 |
2024-01-04 |
Voyager Therapeutics, Inc. |
AAV Capsid Variants and Their Uses
|
|
WO2024003687A1
(en)
|
2022-06-28 |
2024-01-04 |
Pfizer Inc. |
Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
|
|
US20250388626A1
(en)
|
2022-07-06 |
2025-12-25 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2024015892A1
(en)
|
2022-07-13 |
2024-01-18 |
The Broad Institute, Inc. |
Hla-ii immunopeptidome methods and systems for antigen discovery
|
|
US20260021205A1
(en)
|
2022-07-15 |
2026-01-22 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav having aav clade d and clade e capsids and compositions containing same
|
|
JP2025528068A
(ja)
|
2022-08-03 |
2025-08-26 |
ボイジャー セラピューティクス インコーポレイテッド |
血液脳関門を通過させるための組成物及び方法
|
|
WO2024038365A1
(en)
|
2022-08-16 |
2024-02-22 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
|
AU2023331251A1
(en)
|
2022-08-25 |
2025-02-27 |
Takeda Pharmaceutical Company Limited |
Composition for use in the treatment of fabry disease
|
|
EP4584383A1
(en)
|
2022-09-07 |
2025-07-16 |
Universitat Autònoma De Barcelona |
Beta-hexosaminidase vectors
|
|
US20260085328A1
(en)
|
2022-09-08 |
2026-03-26 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
KR20250069606A
(ko)
|
2022-09-15 |
2025-05-19 |
보이저 테라퓨틱스, 인크. |
타우 결합 화합물
|
|
WO2024105638A1
(en)
|
2022-11-18 |
2024-05-23 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of hunter syndrome
|
|
WO2024124019A2
(en)
|
2022-12-07 |
2024-06-13 |
Ginkgo Bioworks, Inc. |
Aav vectors targeting hematopoietic stem cells
|
|
EP4634394A2
(en)
|
2022-12-17 |
2025-10-22 |
The Trustees of The University of Pennsylvania |
Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same
|
|
KR20250129743A
(ko)
|
2022-12-29 |
2025-08-29 |
보이저 테라퓨틱스, 인크. |
Mapt를 조절하기 위한 조성물 및 방법
|
|
EP4658294A2
(en)
|
2023-02-02 |
2025-12-10 |
University of Rochester |
Competitive replacement of glial cells
|
|
AU2023427408A1
(en)
|
2023-02-02 |
2025-09-04 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
EP4698637A1
(en)
*
|
2023-04-18 |
2026-02-25 |
Regents of the University of Minnesota |
Capsid engineered adeno-associated viruses
|
|
WO2024226790A1
(en)
|
2023-04-26 |
2024-10-31 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2024227154A1
(en)
|
2023-04-28 |
2024-10-31 |
Broadwing Bio Llc |
Complement component 3 (c3)-specific antibodies and uses thereof
|
|
AU2024266140A1
(en)
|
2023-05-02 |
2025-09-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for regulating mapt
|
|
WO2024229164A2
(en)
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
KR20260021096A
(ko)
|
2023-05-03 |
2026-02-12 |
보이저 테라퓨틱스, 인크. |
Cdkl5 결핍과 관련된 장애의 치료를 위한 조성물 및 방법
|
|
EP4705487A2
(en)
|
2023-05-03 |
2026-03-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to frataxin deficiency
|
|
WO2024229173A2
(en)
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to ataxin-2
|
|
AU2024266519A1
(en)
|
2023-05-03 |
2025-12-04 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
|
|
TW202444917A
(zh)
|
2023-05-04 |
2024-11-16 |
美商航海家醫療公司 |
Ａａｖ衣殼變異體及其用途
|
|
KR20260010739A
(ko)
|
2023-05-11 |
2026-01-21 |
유니버시티 하스피탈즈 클리블랜드 메디컬 센터 |
항불안 치료
|
|
US12531162B1
(en)
*
|
2023-05-31 |
2026-01-20 |
Northeastern University |
Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
|
|
TW202516019A
(zh)
|
2023-06-29 |
2025-04-16 |
賓州大學委員會 |
具中樞神經系統靶向模體的突變aav及含有其之組成物
|
|
IL326390A
(en)
|
2023-08-10 |
2026-04-01 |
Univ Pennsylvania |
Compositions and methods for treating spinal muscular atrophy
|
|
WO2025038430A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2025038796A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to cdkl5 deficiency
|
|
WO2025038802A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to ataxin-2
|
|
WO2025038805A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
|
|
TW202523846A
(zh)
|
2023-08-16 |
2025-06-16 |
美商航海家醫療公司 |
用於治療與共濟蛋白(frataxin)不足有關之疾病之組合物及方法
|
|
WO2025038795A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
TW202508610A
(zh)
|
2023-08-23 |
2025-03-01 |
大陸商上海瑞宏迪醫藥有限公司 |
醫藥組成物及其用途
|
|
WO2025090427A1
(en)
|
2023-10-23 |
2025-05-01 |
University Of Rochester |
Glial-targeted relief of hyperexcitability in neurodegenerative diseases
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
US12562256B2
(en)
*
|
2023-11-07 |
2026-02-24 |
New York University |
Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
|
|
WO2025102034A1
(en)
|
2023-11-10 |
2025-05-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for barth syndrome
|
|
WO2025106661A1
(en)
|
2023-11-14 |
2025-05-22 |
The Trustees Of The University Of Pennsylvania |
Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof
|
|
WO2025122536A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
WO2025122532A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to ataxin-2
|
|
WO2025122548A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to cdkl5 deficiency
|
|
WO2025122530A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
|
|
WO2025122543A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
|
|
WO2025122644A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for regulating mapt
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
TW202540436A
(zh)
|
2023-12-05 |
2025-10-16 |
美商航海家醫療公司 |
用於治療與共濟蛋白(frataxin)缺陷相關之病症之組合物及方法
|
|
WO2025129157A1
(en)
|
2023-12-15 |
2025-06-19 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treatment of canavan disease
|
|
WO2025137219A1
(en)
|
2023-12-21 |
2025-06-26 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
WO2025147436A1
(en)
|
2024-01-03 |
2025-07-10 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
TW202548022A
(zh)
|
2024-03-03 |
2025-12-16 |
美商帕西奇生物公司 |
用於治療神經退化性病症之重組腺相關病毒
|
|
WO2025235734A2
(en)
|
2024-05-09 |
2025-11-13 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2025250454A1
(en)
|
2024-05-28 |
2025-12-04 |
University Of Rochester |
Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo
|
|
WO2026010722A1
(en)
|
2024-07-03 |
2026-01-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for regulating mapt
|
|
WO2026015039A1
(en)
|
2024-07-09 |
2026-01-15 |
Bial - Portela & Ca., S.A. |
Gene therapy for treatment of syngap1-related epileptic encephalopathy
|
|
WO2026017965A1
(en)
|
2024-07-19 |
2026-01-22 |
The University Court Of The University Of Edinburgh |
Recombinant therapeutic fxn constructs and methods of treating friedreich ataxia and related conditions
|
|
WO2026055342A1
(en)
|
2024-09-04 |
2026-03-12 |
Arsenal Biosciences, Inc. |
Synthetic pathway activators
|